Answer first
A semaglutide research-standard packet should make the expected modified molecular form explicit, then match chromatographic, mass, and composition evidence to that form. The discovery literature describes an engineered GLP-1 analogue with sequence changes and a lipid-derived side chain, so an unqualified name-and-purity record is not enough for a detailed identity review.
- CAS number
- 910463-68-2
- Molecular formula
- C187H291N45O59
- Average molecular weight
- 4114 g/mol average molecular weight
- Exact mass
- 4112.1187318 Da
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-gamma-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH- Aib at position 8 of the GLP-1(7-37) numbering convention
- Arg substitution at position 34
- C18 fatty-diacid side chain attached through a spacer at Lys26
Field-level sources
National Library of Medicine / PubChem · accessed 2026-08-03
Supports: name, cas, formula, weight, exactMass, aliases, molecularForm
Journal of Medicinal Chemistry / PubMed · accessed 2026-08-03
Supports: sequence, peptideDesignation, modifications
Where this framework helps
- Method-development and identity-reference planning
- Comparing analytical evidence across semaglutide research lots
- Preparing a technical data request without commercial purchasing content
Limits to keep visible
- This page does not provide a lot result, specification, or release decision.
- It does not provide medical, dosing, formulation, or administration guidance.
- Exact method performance must be established for the intended laboratory workflow.
Define the expected modified form
The packet should identify the sequence reference, substitution and conjugation context, terminal state where relevant, and expected mass basis. This prevents a generic molecular name from standing in for the actual form under review.
Separate chromatographic and identity evidence
Request chromatographic context for purity or impurity-profile questions and mass evidence for the expected molecular form. If sequence-level localization matters, state that requirement explicitly rather than treating intact mass as a substitute.
Record composition and continuity
Salt form, counter-ion, water, net-content basis, sample preparation, and lot-comparison expectations should be carried into the packet when they affect the research protocol.
Primary and official sources
References used for this page
- Discovery of the Once-Weekly GLP-1 Analogue SemaglutideJournal of Medicinal Chemistry / PubMed
- ICH Q2(R2): Validation of Analytical ProceduresInternational Council for Harmonisation
Visible FAQ
Questions research teams ask
Why does modification context matter for semaglutide identity?
The expected material is not described completely by an unmodified peptide sequence. The identity record should include the relevant substitution and conjugation context used to calculate and interpret the expected form.
What is a reasonable first evidence set?
Begin with an unambiguous identity record, method-qualified chromatographic data, expected-versus-observed mass evidence, and composition fields relevant to the research calculation. Add deeper evidence when the intended purpose requires it.
Does this dossier verify a specific semaglutide lot?
No. It is a planning framework. A lot can only be assessed from the actual lot-specific data, methods, and acceptance context supplied for review.